Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 273-276

  Illi, A ^a,b   Sundberg, S ^a   Ojala Karlsson, P ^c   Scheinin, M ^c   Gordin, A ^a  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

catecholamine metabolism; COMT inhibition; haemodynamics; entacapone; imipramine; systolic time intervals

Indexed keywords

ADRENALIN; CATECHOL METHYLTRANSFERASE; ENTACAPONE; IMIPRAMINE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EXERCISE; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; EPINEPHRINE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; IMIPRAMINE; NOREPINEPHRINE; SINGLE-BLIND METHOD;

EID: 0030476572     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050197     Document Type: Article

References (20)

1. Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden J-B, Männistö PT, Kaakkola S, Pohto P (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 32:841-846
2. Nissinen E, Lindén I-B, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346:262-266
3. Keränen T, Gordín A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145-156
4. Myllylä VV, Sotaniemi KA, Illi A, Keränen T (1993) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45:419-423
5. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and L-dopa metabolism in parkinsonian patients. Neurology 44:77-80
6. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Hammerstad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919
7. Nielsen JR, Johansen T, Arentoft A, Gram LF (1983) Effects of imipramine on the orthostatic changes in blood pressure, heart rate and plasma catecholamines. Clin Exp Pharmacol Physiol 10:497-504
8. Cummings JL (1992) Depression and Parkinson's disease: A review. Am J Psychiatry 149:443-454
9. Spodick DH, Lance VQ (1976) Noninvasive stress testing - Methodology for elimination of the phonocardiogram. Circulation 53:673-676
10. Weissler AM, Harris WS, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37:149-159
11. Scheinin M, Chang WH, Jimerson DC, Linnoila M (1983) Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-performance liquid chromatography using electrochemical detection. Anal Biochem 132:165-170
12. 2-adrenoceptor mediated regulation of norepinephrine release in healthy volunteers. Life Sci 49:75-84
13. Ojala-Karlsson P, Scheinin M (1991) Improved high-performance liquid chromatographic method for the routine determination of unconjugated 3-methoxy-4-hydroxyphenylethyleneglycol in human plasma using solid-phase extraction and electrochemical detection. J Chromatogr 565:131-139
14. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T (1993) The effects of the COMT inhibitor entacapone (OR-611) on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36:451-456
15. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A (1994) COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 32:582-588
16. Veith RC, Raskind MA, Barnes RF, Gumbrecht G, Ritchie JL, Halter JB (1983) Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels. Clin Pharmacol Ther 33:763-769
17. Li Q, Belz GG (1993) Systolic time intervals in clinical pharmacology. Eur J Clin Pharmacol 44:415-421
18. Burgess CD, Turner P (1978) Cardiovascular responses to mianserin hydrochloride: A comparison with tricyclic antidepressant drugs. Br J Clin Pharmacol 5:21S-28S
19. Burgess CD, Wadsworth J, Montgomery S, Turner P (1979) Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients. Postgrad Med J 55: 704-708
20. Taylor DJE, Braithwaite RA (1978) Cardiac effects of tricyclic antidepressant medication: A preliminary study of nortriptyline. Br Heart J 40:1005-1009